Medicine and Dentistry
Vincristine
100%
Neurotoxicity
54%
Chemotherapy
36%
Therapeutic Procedure
36%
Patient
27%
Prophylaxis
18%
Pediatrics Patient
18%
Microtubule
18%
Nervous System Cell
18%
Patient with Cancer
18%
Pathogenesis
9%
Age
9%
Infusion
9%
Disability
9%
Health Care Cost
9%
Side Effect
9%
Mitochondrion
9%
Mitosis
9%
Anticarcinogen
9%
Pain
9%
Neuropathy
9%
Drug
9%
Pyridostigmine
9%
Peripheral Neuropathy
9%
Glutamic Acid
9%
Gabapentin
9%
Chemotherapeutic Agent
9%
Pyridoxine
9%
Genetic Polymorphism
9%
Glutamine
9%
Pediatrics
9%
Consensus
9%
Quality of Life
9%
Race
9%
Pediatric Cancer
9%
Neuroscience
Vincristine
100%
Neurotoxicity
54%
Pediatrics
36%
Chemotherapy
18%
Microtubules
18%
Mitochondrion
9%
Mitosis
9%
Pyridostigmine
9%
Glutamic Acid
9%
Endothelium
9%
Peripheral Neuropathy
9%
Pyridoxine
9%
Glutamine
9%
Gabapentin
9%
Peripheral Neuropathy
9%
Pharmacology, Toxicology and Pharmaceutical Science
Vincristine
100%
Neurotoxicity
54%
Clinical Trial
27%
Side Effect
9%
Pathogenesis
9%
Pyridostigmine
9%
Anticarcinogen
9%
Glutamic Acid
9%
Pain
9%
Drug
9%
Neuropathy
9%
Peripheral Neuropathy
9%
Gabapentin
9%
Glutamine
9%
Death
9%
Pyridoxine
9%
Disability
9%
Biochemistry, Genetics and Molecular Biology
Pediatrics
36%
Mitochondrion
9%
Molecule
9%
Glutamic Acid
9%
Mitosis
9%
Age
9%
Life
9%
Reduction (Chemistry)
9%
Time
9%
Race
9%
Dose
9%
Consensus
9%
Gabapentin
9%
Pyridoxine
9%